Compare AbCellera Biologics Inc (ABCL) vs YieldMax COIN Option Income Strategy ETF (CONY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs YieldMax COIN Option Income Strategy ETF — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while YieldMax COIN Option Income Strategy ETF trades at $19.94. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | CONY | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $8.12 | $103.20 |
52-Week Low | $2.78 | $18.43 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
CONY trades at $20.80, up 1.96% today, amid a bearish technical signal with resistance at $21-$22. The ETF's financial ratios are not disclosed, but it generates weekly dividends, with recent payouts ranging from $0.24 to $0.56. News highlights YieldMax's distribution announcements, though articles warn of underlying declines despite high yields.
The outlook is cautious due to bearish technicals and concerns over sustainability of high distributions. Risks include volatility from options strategies and potential capital erosion. Analyst sentiment is mixed, with no consensus ratings available, suggesting careful evaluation for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →
